Comparative Pharmacology
Head-to-head clinical analysis: VALPROIC ACID versus VIGPODER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VALPROIC ACID versus VIGPODER.
VALPROIC ACID vs VIGPODER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases GABA concentration in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase; also blocks voltage-gated sodium channels and T-type calcium channels.
VIGPODER (vigabatrin) is an irreversible inhibitor of GABA transaminase, leading to increased brain levels of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter.
Initial: 10-15 mg/kg/day orally (divided 2-3 times), increase by 5-10 mg/kg/week; maintenance: 30-60 mg/kg/day. IV infusion: same oral dose, rate ≤20 mg/min.
150 mg orally twice daily with or without food.
None Documented
None Documented
Terminal elimination half-life is 9–16 hours in adults; shorter in children (6–9 hours) and longer in neonates (20–30 hours), elderly, or hepatic impairment (up to 18 hours).
Clinical Note
moderateValproic acid + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Valproic acid is combined with Fluticasone propionate."
Clinical Note
moderateValproic acid + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Valproic acid."
Clinical Note
moderateValproic acid + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Valproic acid."
Clinical Note
moderateValproic acid + Fluconazole
12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl 30–50 mL/min).
Primarily hepatic metabolism (>95%), with less than 3% excreted unchanged in urine. Minor fecal excretion (~5%).
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% via other routes.
Category D/X
Category C
Anticonvulsant
Anticonvulsant
"The metabolism of Fluconazole can be decreased when combined with Valproic acid."